Trinity Biotech Announces Appointment of Clint Severson as a Non-Executive Director

• Press Release
• Source: Trinity Biotech
• On 8:00 am EST, Thursday November 20, 2008

DUBLIN, IRELAND--(MARKET WIRE)--Nov 20, 2008 -- Trinity Biotech plc (NasdaqGS:TRIB - News), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has appointed Clint Severson to its Board as a non-executive director.

Related Quotes

Symbol	Price	Change
TRIB	3.75	-0.06

{"s" : "trib","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Clint Severson is currently Chairman, President and CEO of Abaxis Inc., a NASDAQ traded diagnostics company based in Union City, California. Since November 2006, Mr. Severson has also served on the Board of Directors of CytoCore, Inc. To date he has accumulated over 30 years experience in the medical diagnostics industry and in 2007 he received the prestigious Entrepreneur of the Year award from Forbes Magazine.

The appointment of Clint Severson brings the number of Directors on the Board of Trinity Biotech to six in total of which four are non-executive members.

Commenting on the appointment, Ronan O'Caoimh, Chairman and CEO, said, "I am delighted to announce the appointment of Clint Severson to the Board of Trinity Biotech. With his vast array of experience and achievements in the diagnostics industry Clint represents a very strong addition to the Board."

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

     Contact:
      
     Trinity Biotech plc
     Ronan O'Caoimh
     (353)-1-2769800
     E-mail: Email Contact